We are live on ! Find out more
ISEE

IVERIC bio

Delisted

ISEE was delisted on the 10th of July, 2023.

68 hedge funds and large institutions have $270M invested in IVERIC bio in 2019 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

864% more call options, than puts

Call options by funds: $3.64M | Put options by funds: $378K

672% more capital inflows, than outflows

Capital inflows: $67.6M | Capital outflows: $8.75M

500% more funds holding in top 10

Funds holding in top 10: 1 → 6 (+5)

182% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 11

42% more funds holding

Funds holding: 48 → 68 (+20)

26.69% more ownership

Funds ownership: 37.23% → 63.92% (+27%)

44% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 16

Holders
68
Holders Change
+20
Holders Change %
+41.67%
% of All Funds
1.33%
Holding in Top 10
6
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+500%
% of All Funds
0.12%
New
31
Increased
9
Reduced
16
Closed
11
Calls
$3.64​M
Puts
$378​K
Net Calls
+$3.26​M
Net Calls Change
+$3.26​M

ISEE Hedge Fund Activity: Q4 2019 in Review

68 of the 5,095 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio (ISEE) for Q4 2019, worth a combined $270M — up 1,456% from $17.3M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ISEE positions and 11 closed out — a net gain of 20 holders — while 9 added to existing stakes and 16 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $12.2M. The largest seller was Stonepine Capital Management, cutting an estimated $2.95M.

  • 68 institutional investors held IVERIC bio (ISEE) as of Q4 2019, up from 48 in Q3 2019.
  • Funds reported $270M of IVERIC bio stock for Q4 2019, up 1,456% quarter-over-quarter.
  • 31 funds opened new IVERIC bio positions in Q4 2019 and 11 closed out, a net change of +20 holders.
  • The largest IVERIC bio buyer in Q4 2019 was Consonance Capital Management, an estimated $12.2M added.
  • The largest IVERIC bio seller in Q4 2019 was Stonepine Capital Management, an estimated $2.95M sold.

Based on aggregated 13F filings for Q4 2019.